W Brian Dalton
Overview
Explore the profile of W Brian Dalton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
827
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pasca S, Haldar S, Ambinder A, Webster J, Jain T, Dalton W, et al.
Haematologica
. 2023 Sep;
109(3):948-952.
PMID: 37731390
No abstract available.
2.
Teodorescu P, Pasca S, Choi I, Shams C, Dalton W, Gondek L, et al.
Haematologica
. 2023 Jul;
109(1):337-342.
PMID: 37408441
No abstract available.
3.
Choi I, Ling J, Zhang J, Helmenstine E, Walter W, Bergman R, et al.
Res Sq
. 2023 Apr;
PMID: 37090662
Among the most common genetic alterations in the myelodysplastic syndromes (MDS) are mutations in the spliceosome gene . Such mutations induce specific RNA missplicing events, directly promote ring sideroblast (RS)...
4.
Webster J, Reed M, Tsai H, Ambinder A, Jain T, DeZern A, et al.
Transplant Cell Ther
. 2023 Jan;
29(3):182.e1-182.e8.
PMID: 36587740
Patients age ≥55 years with acute lymphoblastic leukemia (ALL) fare poorly with conventional chemotherapy, with a 5-year overall survival (OS) of ∼20%. Tyrosine kinase inhibitors and novel B cell-targeted therapies...
5.
Karantanos T, Teodorescu P, Arvanitis M, Perkins B, Jain T, DeZern A, et al.
Haematologica
. 2022 Dec;
108(7):1886-1899.
PMID: 36519323
Better understanding of the biology of resistance to DNA methyltransferase (DNMT) inhibitors is required to identify therapies that can improve their efficacy for patients with high-risk myelodysplastic syndrome (MDS). CCRL2...
6.
Ling J, Bygrave A, Santiago C, Carmen-Orozco R, Trinh V, Yu M, et al.
Nat Commun
. 2022 Oct;
13(1):5773.
PMID: 36182931
Precise and reliable cell-specific gene delivery remains technically challenging. Here we report a splicing-based approach for controlling gene expression whereby separate translational reading frames are coupled to the inclusion or...
7.
Karantanos T, Tsai H, Gondek L, DeZern A, Ghiaur G, Dalton W, et al.
Leuk Lymphoma
. 2022 Apr;
63(8):1942-1948.
PMID: 35379077
There are currently no known predictors of myelodysplastic syndrome (MDS)/myeloproliferative overlap neoplasm (MPN) patients' response to hypomethylating agents (HMA). Forty-three patients with MDS/MPN who were treated with HMA during chronic...
8.
Cravero K, Pantone M, Shin D, Bergman R, Cochran R, Chu D, et al.
Oncotarget
. 2022 Feb;
13:373-386.
PMID: 35186194
Activating variants in the PEST region of have been associated with aggressive phenotypes in human cancers, including triple-negative breast cancer (TNBC). Previous studies suggested that PEST domain variants in TNBC...
9.
Karantanos T, Teodorescu P, Perkins B, Christodoulou I, Esteb C, Varadhan R, et al.
Sci Adv
. 2022 Feb;
8(7):eabl8952.
PMID: 35179961
The identification of new pathways supporting the myelodysplastic syndrome (MDS) primitive cells growth is required to develop targeted therapies. Within myeloid malignancies, men have worse outcomes than women, suggesting male...
10.
Webster J, Luznik L, Tsai H, Imus P, DeZern A, Pratz K, et al.
Blood Adv
. 2020 Oct;
4(20):5078-5088.
PMID: 33080006
Allogeneic blood or marrow transplantation (alloBMT) is standard of care for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in first complete remission (CR1). The routine pretransplant and posttransplant...